Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1982 2
1983 3
1984 1
1985 1
1986 2
1987 7
1988 6
1989 3
1990 5
1991 5
1992 4
1994 2
1995 3
1996 4
1997 6
1998 6
1999 7
2000 8
2001 8
2002 4
2003 10
2004 12
2005 16
2006 20
2007 22
2008 19
2009 16
2010 20
2011 29
2012 36
2013 26
2014 34
2015 42
2016 51
2017 45
2018 46
2019 67
2020 59
2021 76
2022 78
2023 75
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

768 results

Results by year

Filters applied: . Clear all
Page 1
Rectal cancer and the pathologist.
Berho M, Bejarano PA. Berho M, et al. Minerva Chir. 2018 Dec;73(6):534-547. doi: 10.23736/S0026-4733.18.07739-8. Epub 2018 Apr 13. Minerva Chir. 2018. PMID: 29658680 Review.
The location of vascular invasion (extramural vs. intramural) may predict aggressive behavior. Pathologists proactively are to choose sections of tumor for molecular testing. ...The modern pathologists play a pivotal part in the care and management of patients suffering fr …
The location of vascular invasion (extramural vs. intramural) may predict aggressive behavior. Pathologists proactively are to choose …
Integrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality.
Zhou J, Foroughi Pour A, Deirawan H, Daaboul F, Aung TN, Beydoun R, Ahmed FS, Chuang JH. Zhou J, et al. EBioMedicine. 2023 Aug;94:104726. doi: 10.1016/j.ebiom.2023.104726. Epub 2023 Jul 25. EBioMedicine. 2023. PMID: 37499603 Free PMC article.
Our models were trained using a dataset of 108 patients from The Cancer Genome Atlas (TCGA), and were externally validated on newly generated dataset from Wayne State University (WSU) of 123 COAD patients and rectal adenocarcinoma (READ) patients in TCGA (N = 52). F …
Our models were trained using a dataset of 108 patients from The Cancer Genome Atlas (TCGA), and were externally validated on newly generate …
Survival outcomes of anal adenocarcinoma versus rectal adenocarcinoma: A retrospective cohort study.
Mankarious MM, Hughes AJ, Berg AS, Scow JS, Jeganathan AN, Kulaylat AS, Deutsch MJ. Mankarious MM, et al. Indian J Gastroenterol. 2023 Oct;42(5):694-700. doi: 10.1007/s12664-023-01394-0. Epub 2023 Aug 31. Indian J Gastroenterol. 2023. PMID: 37648878
BACKGROUND: Anal adenocarcinoma (AA) is a rare malignancy with decreased survival compared to rectal adenocarcinoma (RA). However, AA continues to be treated with similar algorithms compared to rectal cancer with minimal data regarding the efficacy of these treatmen …
BACKGROUND: Anal adenocarcinoma (AA) is a rare malignancy with decreased survival compared to rectal adenocarcinoma (RA). Howe …
Total neoadjuvant therapy approach in rectal adenocarcinoma.
Kang S, Wu C. Kang S, et al. Clin Adv Hematol Oncol. 2021 Nov;19(11):711-718. Clin Adv Hematol Oncol. 2021. PMID: 34807016 Review.
Some of the potential advantages of TNT include improved adherence to treatment, early treatment of micrometastases, and tumor downstaging, with the possibility of observation instead of surgery for those patients with a complete clinical response. ...
Some of the potential advantages of TNT include improved adherence to treatment, early treatment of micrometastases, and tumor downstaging, …
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019: A National Cancer Database Analysis.
Emile SH, Horesh N, Freund MR, Garoufalia Z, Gefen R, Silva-Alvarenga E, Maron DJ, DaSilva G, Wexner SD. Emile SH, et al. JAMA Oncol. 2023 Mar 1;9(3):355-364. doi: 10.1001/jamaoncol.2022.6116. JAMA Oncol. 2023. PMID: 36580307 Free PMC article.
OBJECTIVE: This study aimed to evaluate trends in the characteristics, treatment, and outcomes of rectal adenocarcinoma across 16 years. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, observational case series study used data from the National Cancer …
OBJECTIVE: This study aimed to evaluate trends in the characteristics, treatment, and outcomes of rectal adenocarcinoma across …
Incidental vaginal müllerianosis.
Val-Bernal JF, Mayorga M. Val-Bernal JF, et al. Pathol Res Pract. 2016 Jun;212(6):568-72. doi: 10.1016/j.prp.2016.02.023. Epub 2016 Feb 26. Pathol Res Pract. 2016. PMID: 26970930
In this report, we describe a case of incidental vaginal mullerianosis in a 59-year-old woman who underwent rectosigmoidectomy for rectal adenocarcinoma. In the vaginal cuff removed for neoplastic invasion, a separate multilocular mass measuring 1.5cm was found. ... …
In this report, we describe a case of incidental vaginal mullerianosis in a 59-year-old woman who underwent rectosigmoidectomy for rectal …
Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma.
Hall WA, Li J, You YN, Gollub MJ, Grajo JR, Rosen M, dePrisco G, Yothers G, Dorth JA, Rahma OE, Russell MM, Gross HM, Jacobs SA, Faller BA, George S, Al Baghdadi T, Haddock MG, Valicenti R, Hong TS, George TJ. Hall WA, et al. J Clin Oncol. 2023 Oct 10;41(29):4643-4651. doi: 10.1200/JCO.22.02525. Epub 2023 Jul 21. J Clin Oncol. 2023. PMID: 37478389
PURPOSE: Total neoadjuvant therapy (TNT) is a newly established standard treatment for rectal adenocarcinoma. Current methods to communicate magnitudes of regression during TNT are subjective and imprecise. ...CONCLUSION: MRI alone is a poor tool to distinguish pCR …
PURPOSE: Total neoadjuvant therapy (TNT) is a newly established standard treatment for rectal adenocarcinoma. Current methods …
Prognosis of anal canal adenocarcinoma versus lower rectal adenocarcinoma in Japan: a propensity score matching study.
Saiki Y, Yamada K, Tanaka M, Fukunaga M, Irei Y, Suzuki T. Saiki Y, et al. Surg Today. 2022 Mar;52(3):420-430. doi: 10.1007/s00595-021-02350-1. Epub 2021 Aug 5. Surg Today. 2022. PMID: 34355283
The aim of this retrospective study was to identify the characteristics and PFs of AC, using population-based data in Japan. METHODS: Patients with AC (n = 390) or lower rectal adenocarcinoma (LR) (n = 12,477) diagnosed between1991 and 2006 were enrolled in this stu …
The aim of this retrospective study was to identify the characteristics and PFs of AC, using population-based data in Japan. METHODS: Patien …
Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.
Pai RK, Pai RK. Pai RK, et al. Mod Pathol. 2018 Jan;31(1):4-23. doi: 10.1038/modpathol.2017.87. Epub 2017 Aug 4. Mod Pathol. 2018. PMID: 28776577 Free article. Review.
Neoadjuvant therapy is commonly employed in the treatment of locally advanced rectal adenocarcinoma, hepatic colorectal metastases, esophageal/esophagogastric junction carcinoma, and pancreatic ductal adenocarcinoma. Numerous tumor regression schemes have been used …
Neoadjuvant therapy is commonly employed in the treatment of locally advanced rectal adenocarcinoma, hepatic colorectal metast …
Prediction of tumor budding in patients with rectal adenocarcinoma using b-value threshold map.
Chen F, Zhang S, Ma X, Chen Y, Wang Z, Zhu Y, Bai C, Fu C, Grimm R, Shao C, Lu J, Shen F, Chen L. Chen F, et al. Eur Radiol. 2023 Feb;33(2):1353-1363. doi: 10.1007/s00330-022-09087-6. Epub 2022 Aug 23. Eur Radiol. 2023. PMID: 35997838
Reproducibility was excellent for the ADC (ICC 0.933; CV 8.807%), b(Threshold) values (ICC 0.958; CV 7.399%), and ROI sizes (ICC 0.934; CV 8.425%). Significant negative correlations were observed between mean ADC values and TB grades and positive correlations were obser …
Reproducibility was excellent for the ADC (ICC 0.933; CV 8.807%), b(Threshold) values (ICC 0.958; CV 7.399%), and ROI sizes (ICC 0.934; CV 8 …
768 results